Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology
Growing clinical and preclinical evidence suggests a potential role for the phytocannabinoid cannabidiol (CBD) as a pharmacotherapy for various neuropsychiatric disorders. In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and ne...
Gespeichert in:
| Veröffentlicht in: | Psychopharmacology 2018-02, Vol.235 (2), p.447-458 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 458 |
|---|---|
| container_issue | 2 |
| container_start_page | 447 |
| container_title | Psychopharmacology |
| container_volume | 235 |
| creator | Hudson, Roger Rushlow, Walter Laviolette, Steven R. |
| description | Growing clinical and preclinical evidence suggests a potential role for the phytocannabinoid cannabidiol (CBD) as a pharmacotherapy for various neuropsychiatric disorders. In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type 1 receptors (CB1Rs). CB1R stimulation in the ventral hippocampus (VHipp) potentiates affective memory formation through inputs to the mesolimbic dopamine (DA) system, thereby altering emotional salience attribution. These changes in DA activity and salience attribution, evoked by dysfunctional VHipp regulatory actions and THC exposure, could predispose susceptible individuals to psychotic symptoms. Although THC can accelerate the onset of schizophrenia, CBD displays antipsychotic properties, can prevent the acquisition of emotionally irrelevant memories, and reverses amphetamine-induced neuronal sensitization through selective phosphorylation of the mechanistic target of rapamycin (mTOR) molecular signaling pathway. This review summarizes clinical and preclinical evidence demonstrating that distinct phytocannabinoids act within the VHipp and associated corticolimbic structures to modulate emotional memory processing through changes in mesolimbic DA activity states, salience attribution, and signal transduction pathways associated with schizophrenia-related pathology. |
| doi_str_mv | 10.1007/s00213-017-4766-7 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1955066733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A527676523</galeid><sourcerecordid>A527676523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-5dd2e5c2c724cf59902f8b26f7a944dbf5a42b1346aae02cafe8c250d49107d73</originalsourceid><addsrcrecordid>eNp1ks2O1SAYhhujcY6jF-DGkLhx05F_Tt1NJv4lk-hC14QCPWVSoAId0_vyAqXp6ESjsIDA877h-3ib5jmCFwhC8TpDiBFpIRItFZy34kFzQJTgFkOBHzYHCAlpCWLHs-ZJzjewDnqkj5sz3EFOOk4PzY_P41qiViGo3oXoTAY-mmVSxQLrY3ExqAn4uk0rmFPUNmcXTqCMKS6nEbhQbFJ64zL47spYbyy4taGkqhvdPFdzPy8ZqGCqT46T873TwMRZeRcsyGsu1r8Bzs-T02p3GmICwS4pznnVo1MlVcmsyhineFqfNo8GNWX77G49b76-e_vl6kN7_en9x6vL61ZT0pWWGYMt01gLTPXAug7i4dhjPgjVUWr6gSmKe0QoV8pCrNVgjxozaGiHoDCCnDevdt9a-LfF5iK9y9pOkwo2LlmijjHIuSCkoi__Qm_ikmrvssT1lyA5so7fUyc1WenCEGub9GYqLxkWXHCGN6-Lf1B1GuudjsEOrp7_IUC7QKeYc7KDnJPzKq0SQbklRe5JkTUpckuK3Gp7cffgpffW_Fb8ikYF8A7kehVONt1X9H_Xn0j_zfA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2002038596</pqid></control><display><type>article</type><title>Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hudson, Roger ; Rushlow, Walter ; Laviolette, Steven R.</creator><creatorcontrib>Hudson, Roger ; Rushlow, Walter ; Laviolette, Steven R.</creatorcontrib><description>Growing clinical and preclinical evidence suggests a potential role for the phytocannabinoid cannabidiol (CBD) as a pharmacotherapy for various neuropsychiatric disorders. In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type 1 receptors (CB1Rs). CB1R stimulation in the ventral hippocampus (VHipp) potentiates affective memory formation through inputs to the mesolimbic dopamine (DA) system, thereby altering emotional salience attribution. These changes in DA activity and salience attribution, evoked by dysfunctional VHipp regulatory actions and THC exposure, could predispose susceptible individuals to psychotic symptoms. Although THC can accelerate the onset of schizophrenia, CBD displays antipsychotic properties, can prevent the acquisition of emotionally irrelevant memories, and reverses amphetamine-induced neuronal sensitization through selective phosphorylation of the mechanistic target of rapamycin (mTOR) molecular signaling pathway. This review summarizes clinical and preclinical evidence demonstrating that distinct phytocannabinoids act within the VHipp and associated corticolimbic structures to modulate emotional memory processing through changes in mesolimbic DA activity states, salience attribution, and signal transduction pathways associated with schizophrenia-related pathology.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-017-4766-7</identifier><identifier>PMID: 29063964</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Amphetamines ; Animals ; Antipsychotic Agents - pharmacology ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Biomedical and Life Sciences ; Biomedicine ; Cannabinoids ; Cannabinoids - pharmacology ; Cannabinoids - therapeutic use ; Cannabis ; Dopamine ; Dopamine - metabolism ; Dopaminergic Neurons - drug effects ; Dopaminergic Neurons - metabolism ; Emotions ; Emotions - drug effects ; Emotions - physiology ; Episodic memory ; Hippocampus ; Hippocampus - drug effects ; Hippocampus - metabolism ; Humans ; Limbic Lobe - drug effects ; Limbic Lobe - metabolism ; Memory ; Memory - drug effects ; Memory - physiology ; Mental disorders ; Mental Disorders - drug therapy ; Mental Disorders - metabolism ; Mental Disorders - psychology ; Mesolimbic system ; Neuropsychology ; Neurosciences ; Pathology ; Pharmaceutical research ; Pharmacology/Toxicology ; Phosphorylation ; Phytochemicals - pharmacology ; Phytochemicals - therapeutic use ; Psychiatry ; Psychopathology ; Psychopharmacology ; Rapamycin ; Review ; Salience ; Schizophrenia ; Signal transduction ; Tetrahydrocannabinol ; TOR protein</subject><ispartof>Psychopharmacology, 2018-02, Vol.235 (2), p.447-458</ispartof><rights>Springer-Verlag GmbH Germany 2017</rights><rights>COPYRIGHT 2018 Springer</rights><rights>Psychopharmacology is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-5dd2e5c2c724cf59902f8b26f7a944dbf5a42b1346aae02cafe8c250d49107d73</citedby><cites>FETCH-LOGICAL-c439t-5dd2e5c2c724cf59902f8b26f7a944dbf5a42b1346aae02cafe8c250d49107d73</cites><orcidid>0000-0003-0677-427X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-017-4766-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-017-4766-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29063964$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hudson, Roger</creatorcontrib><creatorcontrib>Rushlow, Walter</creatorcontrib><creatorcontrib>Laviolette, Steven R.</creatorcontrib><title>Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Growing clinical and preclinical evidence suggests a potential role for the phytocannabinoid cannabidiol (CBD) as a pharmacotherapy for various neuropsychiatric disorders. In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type 1 receptors (CB1Rs). CB1R stimulation in the ventral hippocampus (VHipp) potentiates affective memory formation through inputs to the mesolimbic dopamine (DA) system, thereby altering emotional salience attribution. These changes in DA activity and salience attribution, evoked by dysfunctional VHipp regulatory actions and THC exposure, could predispose susceptible individuals to psychotic symptoms. Although THC can accelerate the onset of schizophrenia, CBD displays antipsychotic properties, can prevent the acquisition of emotionally irrelevant memories, and reverses amphetamine-induced neuronal sensitization through selective phosphorylation of the mechanistic target of rapamycin (mTOR) molecular signaling pathway. This review summarizes clinical and preclinical evidence demonstrating that distinct phytocannabinoids act within the VHipp and associated corticolimbic structures to modulate emotional memory processing through changes in mesolimbic DA activity states, salience attribution, and signal transduction pathways associated with schizophrenia-related pathology.</description><subject>Amphetamines</subject><subject>Animals</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cannabinoids</subject><subject>Cannabinoids - pharmacology</subject><subject>Cannabinoids - therapeutic use</subject><subject>Cannabis</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Dopaminergic Neurons - drug effects</subject><subject>Dopaminergic Neurons - metabolism</subject><subject>Emotions</subject><subject>Emotions - drug effects</subject><subject>Emotions - physiology</subject><subject>Episodic memory</subject><subject>Hippocampus</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - metabolism</subject><subject>Humans</subject><subject>Limbic Lobe - drug effects</subject><subject>Limbic Lobe - metabolism</subject><subject>Memory</subject><subject>Memory - drug effects</subject><subject>Memory - physiology</subject><subject>Mental disorders</subject><subject>Mental Disorders - drug therapy</subject><subject>Mental Disorders - metabolism</subject><subject>Mental Disorders - psychology</subject><subject>Mesolimbic system</subject><subject>Neuropsychology</subject><subject>Neurosciences</subject><subject>Pathology</subject><subject>Pharmaceutical research</subject><subject>Pharmacology/Toxicology</subject><subject>Phosphorylation</subject><subject>Phytochemicals - pharmacology</subject><subject>Phytochemicals - therapeutic use</subject><subject>Psychiatry</subject><subject>Psychopathology</subject><subject>Psychopharmacology</subject><subject>Rapamycin</subject><subject>Review</subject><subject>Salience</subject><subject>Schizophrenia</subject><subject>Signal transduction</subject><subject>Tetrahydrocannabinol</subject><subject>TOR protein</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1ks2O1SAYhhujcY6jF-DGkLhx05F_Tt1NJv4lk-hC14QCPWVSoAId0_vyAqXp6ESjsIDA877h-3ib5jmCFwhC8TpDiBFpIRItFZy34kFzQJTgFkOBHzYHCAlpCWLHs-ZJzjewDnqkj5sz3EFOOk4PzY_P41qiViGo3oXoTAY-mmVSxQLrY3ExqAn4uk0rmFPUNmcXTqCMKS6nEbhQbFJ64zL47spYbyy4taGkqhvdPFdzPy8ZqGCqT46T873TwMRZeRcsyGsu1r8Bzs-T02p3GmICwS4pznnVo1MlVcmsyhineFqfNo8GNWX77G49b76-e_vl6kN7_en9x6vL61ZT0pWWGYMt01gLTPXAug7i4dhjPgjVUWr6gSmKe0QoV8pCrNVgjxozaGiHoDCCnDevdt9a-LfF5iK9y9pOkwo2LlmijjHIuSCkoi__Qm_ikmrvssT1lyA5so7fUyc1WenCEGub9GYqLxkWXHCGN6-Lf1B1GuudjsEOrp7_IUC7QKeYc7KDnJPzKq0SQbklRe5JkTUpckuK3Gp7cffgpffW_Fb8ikYF8A7kehVONt1X9H_Xn0j_zfA</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Hudson, Roger</creator><creator>Rushlow, Walter</creator><creator>Laviolette, Steven R.</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0677-427X</orcidid></search><sort><creationdate>20180201</creationdate><title>Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology</title><author>Hudson, Roger ; Rushlow, Walter ; Laviolette, Steven R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-5dd2e5c2c724cf59902f8b26f7a944dbf5a42b1346aae02cafe8c250d49107d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Amphetamines</topic><topic>Animals</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cannabinoids</topic><topic>Cannabinoids - pharmacology</topic><topic>Cannabinoids - therapeutic use</topic><topic>Cannabis</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Dopaminergic Neurons - drug effects</topic><topic>Dopaminergic Neurons - metabolism</topic><topic>Emotions</topic><topic>Emotions - drug effects</topic><topic>Emotions - physiology</topic><topic>Episodic memory</topic><topic>Hippocampus</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - metabolism</topic><topic>Humans</topic><topic>Limbic Lobe - drug effects</topic><topic>Limbic Lobe - metabolism</topic><topic>Memory</topic><topic>Memory - drug effects</topic><topic>Memory - physiology</topic><topic>Mental disorders</topic><topic>Mental Disorders - drug therapy</topic><topic>Mental Disorders - metabolism</topic><topic>Mental Disorders - psychology</topic><topic>Mesolimbic system</topic><topic>Neuropsychology</topic><topic>Neurosciences</topic><topic>Pathology</topic><topic>Pharmaceutical research</topic><topic>Pharmacology/Toxicology</topic><topic>Phosphorylation</topic><topic>Phytochemicals - pharmacology</topic><topic>Phytochemicals - therapeutic use</topic><topic>Psychiatry</topic><topic>Psychopathology</topic><topic>Psychopharmacology</topic><topic>Rapamycin</topic><topic>Review</topic><topic>Salience</topic><topic>Schizophrenia</topic><topic>Signal transduction</topic><topic>Tetrahydrocannabinol</topic><topic>TOR protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hudson, Roger</creatorcontrib><creatorcontrib>Rushlow, Walter</creatorcontrib><creatorcontrib>Laviolette, Steven R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Psychology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hudson, Roger</au><au>Rushlow, Walter</au><au>Laviolette, Steven R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>235</volume><issue>2</issue><spage>447</spage><epage>458</epage><pages>447-458</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Growing clinical and preclinical evidence suggests a potential role for the phytocannabinoid cannabidiol (CBD) as a pharmacotherapy for various neuropsychiatric disorders. In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type 1 receptors (CB1Rs). CB1R stimulation in the ventral hippocampus (VHipp) potentiates affective memory formation through inputs to the mesolimbic dopamine (DA) system, thereby altering emotional salience attribution. These changes in DA activity and salience attribution, evoked by dysfunctional VHipp regulatory actions and THC exposure, could predispose susceptible individuals to psychotic symptoms. Although THC can accelerate the onset of schizophrenia, CBD displays antipsychotic properties, can prevent the acquisition of emotionally irrelevant memories, and reverses amphetamine-induced neuronal sensitization through selective phosphorylation of the mechanistic target of rapamycin (mTOR) molecular signaling pathway. This review summarizes clinical and preclinical evidence demonstrating that distinct phytocannabinoids act within the VHipp and associated corticolimbic structures to modulate emotional memory processing through changes in mesolimbic DA activity states, salience attribution, and signal transduction pathways associated with schizophrenia-related pathology.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29063964</pmid><doi>10.1007/s00213-017-4766-7</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-0677-427X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-3158 |
| ispartof | Psychopharmacology, 2018-02, Vol.235 (2), p.447-458 |
| issn | 0033-3158 1432-2072 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1955066733 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Amphetamines Animals Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Antipsychotics Biomedical and Life Sciences Biomedicine Cannabinoids Cannabinoids - pharmacology Cannabinoids - therapeutic use Cannabis Dopamine Dopamine - metabolism Dopaminergic Neurons - drug effects Dopaminergic Neurons - metabolism Emotions Emotions - drug effects Emotions - physiology Episodic memory Hippocampus Hippocampus - drug effects Hippocampus - metabolism Humans Limbic Lobe - drug effects Limbic Lobe - metabolism Memory Memory - drug effects Memory - physiology Mental disorders Mental Disorders - drug therapy Mental Disorders - metabolism Mental Disorders - psychology Mesolimbic system Neuropsychology Neurosciences Pathology Pharmaceutical research Pharmacology/Toxicology Phosphorylation Phytochemicals - pharmacology Phytochemicals - therapeutic use Psychiatry Psychopathology Psychopharmacology Rapamycin Review Salience Schizophrenia Signal transduction Tetrahydrocannabinol TOR protein |
| title | Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A31%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phytocannabinoids%20modulate%20emotional%20memory%20processing%20through%20interactions%20with%20the%20ventral%20hippocampus%20and%20mesolimbic%20dopamine%20system:%20implications%20for%20neuropsychiatric%20pathology&rft.jtitle=Psychopharmacology&rft.au=Hudson,%20Roger&rft.date=2018-02-01&rft.volume=235&rft.issue=2&rft.spage=447&rft.epage=458&rft.pages=447-458&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-017-4766-7&rft_dat=%3Cgale_proqu%3EA527676523%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2002038596&rft_id=info:pmid/29063964&rft_galeid=A527676523&rfr_iscdi=true |